CDC: Effectiveness of 2-Dose BNT162b2 (Pfizer BioNTech) mRNA Vaccine in Preventing SARS-CoV-2 Infection Among Children Aged 5–11 Years and Adolescents Aged 12–15 Years — PROTECT Cohort
The CDC has released the findings of a recent PROTECT study, assessing the efficacy of two doses of Pfizer-BioNTech vaccine in preventing infection from the Omicron variant amongst children 5 to 11 and adolescents 12 to 15 years of age. The study included clinical data from a cohort of 1,364 participants gathered from July 2021 to February 2022.
The report provides evidence that two doses of the Pfizer-BioNTech vaccine is effective in preventing both asymptomatic and symptomatic SARS-CoV-2 infection in this cohort.
Click on the link below to read the full report:
COVID-19 疫苗的临床建议 - 更新的加强建议
澳大利亚免疫技术咨询小组 (ATAGI) 提供了关于使用加强剂量的 COVID-19 疫苗的最新建议：
- 建议 18 岁及以上的个人接受单次加强剂量的任一 mRNA 疫苗（辉瑞公司 或者 现代), 初级疫苗接种完成后 3 个月。
- 建议 16-17 岁的个人在完成主要课程后 3 个月接受单剂 Comirnaty（辉瑞）作为他们的助推器。其他 COVID-19 疫苗品牌未注册用作该年龄段的加强剂量。
- 同时 Nuvaxovid (Novavax) 未在 TGA 注册用作加强剂量，ATAGI 建议在存在 mRNA 疫苗禁忌症的情况下，可将其用作 18 岁或以上个人的加强剂。支持使用 Nuvaxovid 作为加强剂量的安全性和有效性数据有限，但没有理论上的担忧。
- Vaxzevria（阿斯利康） 不再推荐用作加强剂量。已经接受 Vaxzevria（阿斯利康）作为加强剂的个人不需要重复服用替代品牌的加强剂。
有关 ATAGI 关于使用加强剂量的 COVID-19 疫苗的建议的更多信息，请参阅以下链接：
ATAGI 关于使用加强剂量的 COVID-19 疫苗的建议
Sydney Morning Herald: Fourth COVID vaccine shot found to be highly effective
A preliminary study published by Israel’s Sheba medical centre found that a fourth dose of the COVID-19 vaccine administered to people 60 years and over, made them three times more resistant to serious illness and twice as resistant to infection than thrice-vaccinated people in the same age group.
Moving forward, Pfizer’s chief executive Albert Bourla said annual COVID-19 vaccine boosters would be preferable to more frequent boosters
At this stage, Pfizer is nearly ready to file for approval for a redesigned vaccine that targets Omicron while still protecting against other variants.
要阅读全文，请点击以下链接：
Fourth COVID vaccine shot found to be highly effective
Pfizer and BioNTech provide update on ongoing studies of COVID-19 vaccine
Following a routine review examining the safety and efficacy of the Pfizer-BioNTech by the external Independent Data Monitoring Committee (DMC), data has demonstrated that whilst there were no safety concerns, immunogenicity of a two dose primary course consisting of 3µg doses in the 6 to 24 month-old cohort was met with non-inferiority, but not in the 2 - 5 year old group.
The company has also announced that it will resume studies evaluating a third 3µg dose of COVID-19 vaccine in children 6 months to under 5 years of age in order to select the right dose to maximise the risk-benefit profile in this age group.
For further information on this study and its findings, follow the link below:
Pfizer and BioNTech provide update on ongoing studies of COVID-19 vaccine